Sign In
Buy CBAY
$32.48
+0 (+0%)
At Close: Apr 11, 2024
Is CymaBay Therapeutics (NASDAQ:CBAY) In A Good Position To Deliver On Growth Plans?
10:42am, Friday, 20'th Mar 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
We're Keeping An Eye On CymaBay Therapeutics's (NASDAQ:CBAY) Cash Burn Rate
10:30am, Friday, 20'th Mar 2020
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Connor Clark & Lunn Investment Management Ltd. Acquires Shares of 27,650 CymaBay Therapeutics Inc (NASDAQ:CBAY)
10:28am, Friday, 20'th Mar 2020
Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) in the fourth quarter, Holdings Channel.com reports. The fund purchased 27,6
B. Riley Lowers CymaBay Therapeutics (NASDAQ:CBAY) Price Target to $1.50
09:24am, Friday, 20'th Mar 2020
CymaBay Therapeutics (NASDAQ:CBAY) had its price objective reduced by equities researchers at B. Riley from $2.00 to $1.50 in a research note issued to investors on Wednesday, BenzingaRatingsTable rep
Research Analysts Set Expectations for CymaBay Therapeutics Inc's Q1 2020 Earnings (NASDAQ:CBAY)
05:20am, Friday, 20'th Mar 2020
CymaBay Therapeutics Inc (NASDAQ:CBAY) – Investment analysts at B. Riley issued their Q1 2020 earnings per share (EPS) estimates for CymaBay Therapeutics in a research note issued on Tuesday, March
Citigroup Maintains Buy on CymaBay Therapeutics, Lowers Price Target to $1.6
12:00am, Friday, 20'th Mar 2020CymaBay Therapeutics (CBAY) Receives a Buy from Oppenheimer
05:57pm, Wednesday, 18'th Mar 2020
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on CymaBay Therapeutics (CBAY). The company's shares closed last Monday at
CymaBay Therapeutics (CBAY) Receives a Buy from Oppenheimer
05:57pm, Wednesday, 18'th Mar 2020
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report).
B. Riley FBR Maintains Neutral on CymaBay Therapeutics, Lowers Price Target to $1.5
12:00am, Wednesday, 18'th Mar 2020B.Riley FBR Remains a Hold on CymaBay Therapeutics (CBAY)
02:37pm, Tuesday, 17'th Mar 2020
In a report released today, Mayank Mamtani from B.Riley FBR maintained a Hold rating on CymaBay Therapeutics (CBAY), with a price target of $1.50. The
B.Riley FBR Remains a Hold on CymaBay Therapeutics (CBAY)
02:37pm, Tuesday, 17'th Mar 2020
In a report released today,
Mayank Mamtani
from B.Riley FBR maintained a
Hold
rating on CymaBay Therapeutics (
CBAY
–
Research Report
), with a price target of
$1.50
. The company’s shares closed
CymaBay Therapeutics (CBAY) Receives a Hold from Stifel Nicolaus
02:37pm, Monday, 16'th Mar 2020
Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on CymaBay Therapeutics (CBAY) on March 12 and set a price target of $4.00. The company's
CymaBay Therapeutics (CBAY) Receives a Hold from Stifel Nicolaus
02:37pm, Monday, 16'th Mar 2020
Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on CymaBay Therapeutics (CBAY – Research Report) on March 12 and
CymaBay Therapeutics (NASDAQ:CBAY) Raised to Overweight at Cantor Fitzgerald
10:32am, Monday, 16'th Mar 2020
Cantor Fitzgerald upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY) from a neutral rating to an overweight rating in a research note published on Friday, BenzingaRatingsTable reports. Cantor Fitzg
Mar 16, 2020 (The Expresswire) --
Global “Peroxisome Proliferator Activated Receptor Delta Market” Report 2020 is a comprehensive, professional report...
